Skip to main content
. 2013 Jun 6;68(7):921–928. doi: 10.1111/all.12171

Figure 1.

Figure 1

Study design: This was a double-blind, placebo-controlled, triple cross-over study of 20 patients with cold contact urticaria (CCU) treated daily for 7 days with bilastine (B) 20, 40 and 80 mg and placebo. Measurements were taken of critical temperature threshold (CTT) and skin microdialysis performed to assess histamine and cytokine generation.